Cargando…

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test

This scientific commentary refers to ‘Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease’, by Mattsson-Carlgren et al. (doi:10.1093/brain/awaa286).

Detalles Bibliográficos
Autores principales:	Teunissen, Charlotte E, Thijssen, Elisabeth H, Verberk, Inge M W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Scientific Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719020/ https://www.ncbi.nlm.nih.gov/pubmed/33278818 http://dx.doi.org/10.1093/brain/awaa329

Ejemplares similares

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Thijssen, Elisabeth H., et al.
Publicado: (2021)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
por: VandeVrede, Lawren, et al.
Publicado: (2023)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
por: Hanes, Jozef, et al.
Publicado: (2020)

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Neurofeedback for tinnitus treatment: an innovative method with promising potential
por: Kleinjung, Tobias, et al.
Publicado: (2023)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Ambulatory Blood Pressure Monitoring – Kids Need it Too?
por: Pais, P., et al.
Publicado: (2017)

Multiple chemical scaffolds inhibit a promising Leishmania drug target
por: Walkinshaw, Malcolm
Publicado: (2014)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Flavouring Group Evaluation 217 Revision 3 (FGE.217Rev3): consideration of genotoxic potential for α,β‐unsaturated ketones and precursors from chemical subgroup 4.1 of FGE.19: lactones
por: Younes, Maged, et al.
Publicado: (2023)

Vessel wall imaging: a promising enhancement in the management of inflammatory intracranial vasculopathy
por: Yang, Dixon, et al.
Publicado: (2022)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Music, memory and mechanisms in Alzheimer’s disease
por: Clark, Camilla N., et al.
Publicado: (2015)

Scientific Opinion on Flavouring Group Evaluation 217 Revision 2 (FGE.217Rev2), consideration of genotoxic potential for α,β‐unsaturated ketones and precursors from chemical subgroup 4.1 of FGE.19: lactones
por: Younes, Maged, et al.
Publicado: (2019)

MERS Vaccine Candidate Offers Promise, but Questions Remain
por: Menachery, Vineet D.
Publicado: (2015)

Commentary: AADI: New kid on the block
por: Pathak-Ray, Vanita
Publicado: (2018)

Making the most of common impact metrics: promising approaches that need further study
por: Grove, John, et al.
Publicado: (2013)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Detecting early changes in Alzheimer’s disease with graph theory
por: Pereira, Joana B
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_87kdj59cqrjemrvbbi4blfcd99